Mary Lynne Hedley's Net Worth
$49.7 Million
Who is Mary Lynne Hedley?
Mary Lynne Hedley has an estimated net worth of $49.7 Million. This is based on reported shares across multiple companies, which include VEEVA SYSTEMS INC, Abraxis BioScience, Inc., Receptos, Inc., Centessa Pharmaceuticals plc, bluebird bio, Inc., Millendo Therapeutics, Inc., TESARO, Inc., ELI LILLY & Co, and MGI PHARMA INC.
SEC CIK
Mary Lynne Hedley's CIK is 0001340823
Past Insider Trading and Trends
2023 was Mary Lynne Hedley's most active year for acquiring shares with 18 total transactions. Mary Lynne Hedley's most active month to acquire stocks was the month of May. 2019 was Mary Lynne Hedley's most active year for disposing of shares, totalling 14 transactions. Mary Lynne Hedley's most active month to dispose stocks was the month of December. 2006 saw Mary Lynne Hedley paying a total of $1,134,750.00 for 95,000 shares, this is the most they've acquired in one year. In 2019 Mary Lynne Hedley cashed out on 1,832,266 shares for a total of $44,278,875.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
VEEVA SYSTEMS INC (VEEV) Snapshot price: $209.33
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +7.32% | 302 |
—
|
—
| 4.43K |
Mar 1
| |||
Form 4
| -1.97% | -83.00 |
$191.02 | -$15,854.30 | 4.13K |
Scheduled
|
Dec 27 - Dec 28
| ||
Form 4
| +7.75% | 303 |
—
|
—
| 4.21K |
Dec 1
| |||
Form 4
| +8.37% | 302 |
—
|
—
| 3.91K |
Sep 1
| |||
Form 4
| -6.00% | -230.00 |
$207.87 | -$47,809.18 | 3.61K |
Jul 12 - Jul 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
| +9.29% | 326 |
—
|
—
| 3.84K |
Jun 1
| |||
Form 4
| +10.27% | 327 |
—
|
—
| 3.51K |
Mar 1
| |||
Form 4
| +11.41% | 326 |
—
|
—
| 3.18K |
Dec 1
| |||
Form 4
| +12.92% | 327 |
—
|
—
| 2.86K |
Sep 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
| +8.44% | 197 |
—
|
—
| 2.53K |
Jun 1
| |||
Form 4
| +9.22% | 197 |
—
|
—
| 2.33K |
Mar 1
| |||
Form 4
| +10.16% | 197 |
—
|
—
| 2.14K |
Dec 1
| |||
Form 4
| +11.31% | 197 |
—
|
—
| 1.94K |
Sep 1
| |||
Form 4
| -5.12% | -94.00 |
$314.81 | -$29,592.14 | 1.74K |
Scheduled
|
Jul 15
| ||
Form 4
| +13.75% | 222 |
—
|
—
| 1.84K |
Jun 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 23
| |||
Form 4
| -5.56% | -95.00 |
$270.66 | -$25,712.70 | 1.61K |
Scheduled
|
Apr 14
| ||
Form 4
| +15.01% | 223 |
—
|
—
| 1.71K |
Mar 25
| |||
Form 4
| -6.01% | -95.00 |
$288.54 | -$27,411.30 | 1.49K |
Scheduled
|
Jan 11
| ||
Form 4
| +16.42% | 223 |
—
|
—
| 1.58K |
Dec 25
| |||
Form 4
| +19.54% | 222 |
—
|
—
| 1.36K |
Sep 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 25
| |||
Form 4
| +11.15% | 114 |
—
|
—
| 1.14K |
Jun 16
| |||
Form 4
| +50.07% | 341 |
—
|
—
| 1.02K |
May 16
| |||
Form 4
| +100.29% | 341 |
—
|
—
| 681 |
Feb 16
| |||
Form 4
|
∞
| 340 |
—
|
—
| 340 |
Nov 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Abraxis BioScience, Inc. No price found
Executive VP Ops & CSO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 25K |
—
|
—
| 25K |
Jul 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Receptos, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -7.40K |
—
|
—
|
0
|
Aug 27
| |||
Form 4
|
∞
| 7.4K |
—
|
—
| 7.4K |
May 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Centessa Pharmaceuticals plc (CNTA) Snapshot price: $7.58
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
bluebird bio, Inc. (BLUE) Snapshot price: $0.9333
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +37.04% | 1K |
—
|
—
| 3.7K |
Jun 20
| |||
Form 4
|
∞
| 2.7K |
—
|
—
| 2.7K |
Sep 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||